All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Lymphatic filariasis is caused by the parasitic, mosquito-borne filarial round-worm *Wuchereria bancrofti* and has been classified by the World Health Organization (WHO) as a neglected tropical disease. The mosquito vector transmits the immature worms, known as microfilariae (Mf), from human to human in 61 endemic countries. The WHO recommends mass drug administration (MDA) for affected communities, as a key element of strategies to control and ultimately eliminate lymphatic filariasis as a public health problem.\[[@pntd.0008106.ref001]\]

Three anti-parasitic drugs, albendazole, diethylcarbamazine and ivermectin, have therapeutic efficacy against lymphatic filariasis and so have been included by WHO in MDA recommendations, with the specific choice of agents dependent on the presence of other endemic pathogens.\[[@pntd.0008106.ref002]\] The precise mechanism of action of these medications on the filarial worm are not fully understood, but efficacy studies have determined macrofilaricidal and microfilaricidal activity when used in either two drug combination. The standard MDA in the Pacific is based on the dual combination of diethylcarbamazine and albendazole (known together as DA). Eleven countries, including Egypt, Thailand and Tonga, have achieved elimination targets and are under surveillance, but others, including eight countries in the Western Pacific Region such as Samoa, Philippines and Fiji, have not done so despite multiple rounds of MDA.\[[@pntd.0008106.ref001]\]

Elephantiasis, one of the severe complications of lymphatic filariasis, was first reported from Fiji in 1841, on the island of Rotuma \[[@pntd.0008106.ref003]\], and a national survey in the 1940s observed a Mf prevalence of 12.7%.\[[@pntd.0008106.ref004]\] After limited success with vector control \[[@pntd.0008106.ref005], [@pntd.0008106.ref006]\], the Ministry of Health commenced a national MDA with diethylcarbamazine in 1969.\[[@pntd.0008106.ref007]\] In 1999, Fiji joined the Pacific Programme to Eliminate Lymphatic Filariasis and delivered annual MDA from 2002 using DA. However, despite reportedly adequate DA treatment coverage above 65%, lymphatic filariasis has remained endemic in specific areas of Fiji.\[[@pntd.0008106.ref001]\]

Combining the three active agents into the one MDA combination, known as IDA, does not create any drug-drug interactions, and is superior to DA in clearing microfilaremia at least as long as 36 months after a single round of treatment.\[[@pntd.0008106.ref008]--[@pntd.0008106.ref010]\] With more effective filariasis treatments it is expected that persons with microfilaremia will experience more adverse events (AEs), attributable to the response to dead or dying parasites.\[[@pntd.0008106.ref011], [@pntd.0008106.ref012]\] This effect on AEs was reported from a small efficacy trial based in Papua New Guinea.\[[@pntd.0008106.ref008], [@pntd.0008106.ref009]\] Fiji joined a 5-site international collaboration to examine the effect of IDA in a larger number of participants across multiple geographic settings. This large global study of IDA confirmed more AEs occurred, but the majority were mild and transient, and that this combination was a safe strategy for community control of filariasis.\[[@pntd.0008106.ref013], [@pntd.0008106.ref014]\]

Ivermectin is also efficacious against two other neglected tropical diseases endemic in Fiji, scabies and soil-transmitted helminths (STH).\[[@pntd.0008106.ref002], [@pntd.0008106.ref015]--[@pntd.0008106.ref018]\] A national survey of scabies in 2007 found that all age groups and regions of Fiji are affected, with an estimated national prevalence of 18.5%.\[[@pntd.0008106.ref016], [@pntd.0008106.ref019]\] Soil-transmitted helminths are also common in Fiji with a prevalence as high as 45% in school-aged children.\[[@pntd.0008106.ref020]--[@pntd.0008106.ref022]\] Because the medications in the IDA drug combination have activity against scabies and STH in addition to lymphatic filariasis, MDA with IDA represents an integrated intervention against three neglected tropical diseases. Successful treatment of scabies and STH is expected to induce mild and transient symptoms primarily pruritus (scabies) and abdominal pain (STH).\[[@pntd.0008106.ref016], [@pntd.0008106.ref018]\] We aimed to evaluate the safety of IDA in Fiji, providing a detailed account of AEs following DA and IDA mass drug administration in Fiji and an analysis of factors associated with their occurrence including filariasis, scabies, and STH infections.

Methods {#sec002}
=======

We conducted a cluster randomised trial to compare the safety of MDA with DA and IDA. We chose a cluster randomised design because the intervention is implemented at the community level. The study procedures as applied to individuals were consistent with the protocol of the multi-site safety trial of IDA ([S1 Protocol](#pntd.0008106.s001){ref-type="supplementary-material"}).\[[@pntd.0008106.ref013]\]

Ethical approvals, trial registration and oversight {#sec003}
---------------------------------------------------

Relevant government ministries and district offices in Fiji approved the engagement of communities on these islands. The protocol was reviewed by the Royal Children's Hospital Melbourne Human Research Ethics Committee (reference 36205) and Fiji National Health Research and Ethics Review Committee (reference 2016.81.MC). The trial was registered (Clinitrials.gov NCT03177993 and ANZCTR N12617000738325). An independent Data Safety Monitoring Board of six experts reviewed the protocol and met periodically throughout the study to review reports.

Setting {#sec004}
-------

The study was conducted in Fiji, an island nation in the Southwest Pacific with a population in the most recent census (2017) of 884,887, a median age of 27.5 years and with 56% located in urban settings.\[[@pntd.0008106.ref023]\] People are predominantly of Melanesian, Polynesian or Indian descent. There are four governmental divisions: Central, Northern, Eastern, and Western.

The Eastern Division was chosen for the study because it has the highest Mf prevalence in the country of 2.2% in 2007. \[[@pntd.0008106.ref024]\] Two of the divisions islands from this region, Rotuma and Gau, were selected study sites. Both had previously received at least 10 rounds of MDA and, based on filarial antigen prevalence, were due for a further round in 2017.\[[@pntd.0008106.ref025]\] The islands met other criteria for being study sites, including having reliable communications, a hospital, and an airstrip for medical evacuation.

Trial design {#sec005}
------------

Villages were designated as clusters. All 35 villages on the two islands agreed to participate in this study prior to randomisation. An independent statistician generated randomised treatment allocation using Stata software in a 1:1:1 ratio stratified by island to either DA, IDA1 (ivermectin administered with diethylcarbamazine and albendazole) or IDA2 (same as IDA1, plus a second dose of ivermectin on day 8). The IDA2 group was included to evaluate the community effectiveness of one versus two doses of ivermectin not reported here. Our study design differed from the global study by including all community members regardless of eligibility for LF treatment in order to allow community assessments for all three infections at both timepoints. For the purpose of analysing the safety of IDA up to 7 days, the IDA1 and IDA2 groups were identical, so they were combined for safety analyses.

Treatments {#sec006}
----------

Albendazole was provided as a fixed oral dose of 400mg. Diethylcarbamazine and ivermectin were dosed according to weight and whole tablet ranges, aiming for 6mg/kg and 200μg/kg respectively, ([S1 Table](#pntd.0008106.s004){ref-type="supplementary-material"}). Participants and assessors were unblinded to treatment given.

Participants were excluded from receiving either IDA or DA treatment if they were less than 2 years of age or 15 kg in weight, were pregnant, breastfeeding within 7 days of delivery, or known to have a severe illness or allergy to study drugs. All women of child-bearing age were asked on the timing of their last menses. If menses was more than 4 weeks or unknown, a urine pregnancy test was offered. No contraceptive measures were provided or recommended, consistent with WHO policy for LF MDA. Additionally, those in villages allocated to IDA were excluded from taking ivermectin if aged less than 5 years. Topical permethrin cream 5%, which is active against scabies, was provided to all individuals excluded from taking ivermectin. It was also offered to individuals in the DA group identified at baseline screening as having scabies and to their household contacts ([S1 Fig](#pntd.0008106.s002){ref-type="supplementary-material"}).

All oral medication was taken under direct observation by a study team member. Permethrin application was not observed. Instructions to adults in affected households recommended permethrin to be applied over the whole body for 8 hours overnight (4 hours for children less than 2 months of age) before washing off.

Community engagement and enrolment {#sec007}
----------------------------------

Prior to enrolment there was extensive community engagement in each village including liaison with leaders and health representatives, and an interactive presentation. This introduced and explained the study, the treatment group to which their village had been allocated, expected date of enrolment, and the different procedures on enrolment day: individual consent, screening for infections and administration of study medications. Anyone living in the village at the time of MDA was invited to the community central meeting place to enrol regardless of eligibility for MDA. Outreach visits to homes were conducted to allow people with poor mobility to participate. Participants 13 years and older were asked to provide written consent. Parental/guardian consent was required for all people aged less than 18 years and for adults without capacity to consent. For individuals 13--17 years dual consent was required. Written material was provided in English and the Fijian language, iTaukei, and staff members provided verbal translation in iTaukei and Rotuman as required. Representatives from each village assisted the study team in creating up-to-date lists of village residents by household and reasons for non-participation: temporarily away or declined.

Safety assessments {#sec008}
------------------

The primary outcome of safety of IDA was evaluated at the individual and cluster levels. A training package from the global study \[[@pntd.0008106.ref013]\] was provided to all staff to ensure consistency of reporting between staff and across sites. Safety was assessed in two periods, consistent with the timing of AEs observed in previous studies.\[[@pntd.0008106.ref008]--[@pntd.0008106.ref011]\] Active follow-up of all participants occurred daily in the first two days following treatment, when more severe symptoms are expected with death of microfilariae.\[[@pntd.0008106.ref011]\] For continuity, participants were seen by the same nurse on the day of taking tablets and day 1 and day 2 afterwards, and asked a standard open-ended question about their health. During days 3 to 7 after treatment, monitoring comprised of two activities: 1) participants were asked to notify a study representative if they were unwell and required assessment, and 2) participants previously identified as having an AE judged moderate or worse were assessed each day, with assessments only stopping if symptoms improved to mild severity or resolved completely ([S2 Fig](#pntd.0008106.s003){ref-type="supplementary-material"}).

Symptoms were classified using terms from Medical Dictionary for Regulatory Activities \[[@pntd.0008106.ref026]\], and were graded based on the impact on daily activities of the participant: from mild (no impact); moderate (unable to engage in normal functional activities like work or school); severe (unable to undertake personal activities of daily living); or life-threatening ([S2 Table](#pntd.0008106.s005){ref-type="supplementary-material"}).\[[@pntd.0008106.ref027]\] Further, participants identified with an AE judged moderate or worse had vital signs taken by the study nurse. Participants with events graded as severe or life-threatening, or graded as moderate with abnormal vital signs, symptoms of unclear cause or generating nurse concern, were reviewed by a local doctor for full examination, management and assessment of whether the event met the criteria for a serious AE ([S2 Fig](#pntd.0008106.s003){ref-type="supplementary-material"}).

A serious AE was defined as one resulting in at least one of the following outcomes: death, life-threatening event, new or prolongation of a hospital admission, persistent or significant disability/incapacity, congenital anomaly, or other serious health event requiring medical intervention to prevent one of the other outcomes listed above. All serious AEs were discussed with the Medical Monitor, an offsite independent senior doctor trained in safety reporting. The Global Medical Monitor reviewed all serious AE reports before they were reported to the Data Safety Monitoring Board, ethics committees and medication suppliers.

Parasitology assessments {#sec009}
------------------------

Participants were tested at baseline for the presence of parasitic infections known to be sensitive to one or more of the study drugs. From an efficacy perspective, this testing would serve as a baseline for subsequent assessments. From a safety perspective, it was important to be able to relate potential effects of co-infection on drug efficacy and AEs.

### Lymphatic filariasis {#sec010}

The prevalence of filarial infection was determined by two standard methods. Circulating filarial antigen (CFA) was detected by placing approximately 75 μl of capillary blood onto the rapid diagnostic test, Alere Filariasis Test Strip (FTS, Alere Scarborough, Inc., Scarborough, ME, USA). The CFA was quantified by comparing the colour strength of the test strip against the control line at 10 minutes, scored as: CFA1 (weak positive); CFA2 (medium positive); and CFA3 (strong positive).\[[@pntd.0008106.ref028]\] The second method detects active infection with *W*. *bancrofti* by light microscopy for Mf in a 60 μl stained capillary blood smear. Mf testing was only performed for participants with a positive CFA result only. Each blood smear was read independently by two laboratory technicians.\[[@pntd.0008106.ref029], [@pntd.0008106.ref030]\]

### Scabies {#sec011}

Scabies was diagnosed by trained nurses by identifying pruritic inflammatory papules in a typical distribution.\[[@pntd.0008106.ref031]\]

### Soil-transmitted helminths {#sec012}

Stool pots and collection kits were distributed to the community prior to enrolment, and participants asked to bring in fresh stool on the day of enrolment, and prior to administration of study drug. Stool was processed by the Kato-Katz method within 12 hours of collection.\[[@pntd.0008106.ref032]\] Smears were prepared in duplicate with each one read independently by one of two trained laboratory technicians. A stool sample was considered positive if either technician identified eggs of *Ascaris*, *Trichuris* or hookworm.

Data management {#sec013}
---------------

Data were captured in real time into an electronic data capture system developed specifically for the Fiji trial site by CliniOps (Fremont, CA, USA). The system allowed study team members to enter de-identified information at enrolment for each participant, and linked information collected at subsequent visits to the participant's record.

Statistical methods {#sec014}
-------------------

We reported our results consistent with Consolidated Standards of Reporting Trials (CONSORT) recommendations for cluster trials ([S3 Table](#pntd.0008106.s006){ref-type="supplementary-material"}).\[[@pntd.0008106.ref033], [@pntd.0008106.ref034]\] Data were analysed as prospectively planned and in accordance with International Conference on Harmonisation Statistical Principles for Clinical Trials Guideline E9. A statistical analysis plan was written for the main study and followed for the Fiji study. The Fiji site differs from the global study analysis by including children aged 2--4 years who received LF treatment with DA according to WHO guidelines. We described AEs by absolute number, severity, symptoms, treatment group, island, sex, age-group and parasitological status at baseline. We used logistic regression adjusted for clustering by village and stratification by island for statistical significance. We compared AEs between subgroups in univariate and multivariate generalised linear models, adjusting for clustering by village and stratification by island. We did not include STH results in the multivariate analysis due to the low number of processed samples. Filariasis infection was represented only by Mf results for the multivariate analysis. For sub-group analyses with small denominators, statistical significance has been determined using Fischer's exact test without any adjustment for village clustering or island stratification.

### Sample size {#sec015}

Fiji was part of a multi-site study (other sites included Haiti, India, Indonesia and Papua New Guinea) that enrolled 26,836 participants 5 years and older.\[[@pntd.0008106.ref013]\] This sample size is powered to detect serious AEs with a frequency of less than 0.1%. This level of serious AE detection is recommended by WHO for endorsement of new public health treatments.\[[@pntd.0008106.ref035]\] The individual sites are not powered for this primary outcome. The sample size of groups in Fiji was adequate to evaluate the effect of one versus two doses of ivermectin on scabies, not reported here.

Results {#sec016}
=======

Enrolment {#sec017}
---------

The total resident population of the two islands was 4610: 1994 in 17 villages on Rotuma and 2616 in 18 villages on Gau ([Fig 1](#pntd.0008106.g001){ref-type="fig"}, [Table 1](#pntd.0008106.t001){ref-type="table"}). The median village size was 108 people, range 18 to 298 ([S4 Table](#pntd.0008106.s007){ref-type="supplementary-material"}). Participants were recruited over a four-month period from July 2017 to November 2017. The total number consented was 3812 (82.7% enrolment coverage). There was 80% participation for the villages randomised for DA treatment and 84.1% for those randomized for IDA (85.9% for IDA1 and 82.6% for IDA2). There were 449 people (9.7%) temporarily away from their village at the time of the enrolment visit and 349 people (7.6%) who declined (DA group 10.4%, IDA group 6%, [S5 Table](#pntd.0008106.s008){ref-type="supplementary-material"}). The age and sex distribution of enrolled participants was similar to the overall population distribution of the two islands ([S4 Table](#pntd.0008106.s007){ref-type="supplementary-material"}). The median height and weight for the 2161 participants aged 18 years and older was 169 cm (IQR 163--175 cm) and 84.7 kg (IQR 72.5--97.7 kg) respectively.

![CONSORT flow diagram detailing village cluster randomisation, individual enrolment, treatment received, safety monitoring follow-up and resulting total including in analyses.\
DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two doses, diethylcarbamazine and albendazole.](pntd.0008106.g001){#pntd.0008106.g001}

10.1371/journal.pntd.0008106.t001

###### Participant demographic characteristics and baseline parasitic infection prevalence by treatment group.

![](pntd.0008106.t001){#pntd.0008106.t001g}

                                                                                                                      DA     IDA            Total                                                                     
  ---------------------------------------------------- -------------------------------------------------------------- ------ -------------- -------------- ------ -------------- -------------- ------ -------------- --------------
  Enrolment                                            Total population                                               1616                                 2994                                 4610                  
                                                       Total consented                                                1293   80.0                          2519   84.1                          3812   82.7           
  Sex                                                  Male                                                           673    52.0           (49.7--54.4)   1293   51.3           (49.4--53.2)   1966   51.6           (50.1--53.1)
                                                       Female                                                         620    48.0           (45.6--50.3)   1226   48.7           (46.8--50.6)   1846   48.4           (46.9--49.9)
  Age (years)                                          Median (IQR)                                                   27                    (10--48)       24                    (10--46)       25                    (10--47)
                                                       \<2                                                            38     2.9            (2.1--4.0)     55     2.2            (1.5--3.1)     93     2.4            (1.9--3.1)
                                                       2--4                                                           80     6.2            (5.3--7.3)     168    6.7            (5.6--7.9)     248    6.5            (5.7--7.4)
                                                       5--9                                                           182    14.1           (11.4--17.3)   359    14.3           (12.3--16.5)   541    14.2           (12.6--16.0)
                                                       10--14                                                         172    13.3           (10.6--16.6)   359    14.3           (12.2--16.6)   531    13.9           (12.3--15.8)
                                                       15--24                                                         134    10.4           (8.2--13.0)    328    13.0           (7.6--21.4)    462    12.1           (8.2--17.5)
                                                       25--34                                                         154    11.9           (9.3--15.1)    264    10.5           (9.2--11.9)    418    11.0           (9.7--12.3)
                                                       35--49                                                         236    18.3           (15.8--21.0)   449    17.8           (15.5--20.4)   685    18.0           (16.2--19.9)
                                                       50--64                                                         207    16.0           (12.7--20.0)   358    14.2           (12.0--16.8)   565    14.8           (13.0--16.9)
                                                       ≥65                                                            90     7.0            (5.8--8.3)     179    7.1            (5.6--8.9)     269    7.1            (6.0--8.3)
  LF                                                   Total assessed CFA                                             1239                                 2420                                 3659                  
                                                       Total CFA positive                                             186    15.0           (8.8--24.4)    330    13.6           (10.0--18.3)   516    14.1           (11.3--17.5)
                                                       CFA1---weak positive                                           64     5.2            (3.7--7.2)     107    4.4            (3.2--6.1)     171    4.7            (3.8--5.8)
                                                       CFA2---medium positive                                         59     4.8            (2.4--9.4)     98     4.1            (3.0--5.4)     157    4.3            (3.3--5.5)
                                                       CFA3---strong positive                                         63     5.1            (2.1--11.6)    125    5.2            (3.4--7.8)     188    5.1            (3.6--7.4)
  LF                                                   Microfilariae positive[^a^](#t001fn002){ref-type="table-fn"}   47     3.8            (1.5--9.1)     93     3.9            (2.6--5.8)     140    3.8            (2.6--5.6)
                                                       Geometric mean density Mf/ml                                   239                   (149--383)     183                   (128--260)     200                   (151--264)
  Scabies                                              Identified[^b^](#t001fn003){ref-type="table-fn"}               176    13.6           (7.9--22.4)    337    13.4           (9.9--17.9)    513    13.5           (10.4--17.3)
  STH                                                  Stool specimen assessed                                        268    20.7                          658    26.1                          926    24.3           
                                                       Positive microscopy                                            35     13.1           (6.3--25.1)    136    20.7           (13.2--30.9)   171    18.5           (12.7--26.1)
  LF Treatment[^c^](#t001fn004){ref-type="table-fn"}   1216                                                           94.0   (92.5--95.3)   2396           95.1   (93.9--96.1)   3612           94.8   (93.9--95.5)   
  Any follow-up after LF treatment                     1216                                                           100    \-             2382           99.4   (98.5--99.8)   3598           99.6   (99.0--99.9)   

DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; IQR: interquartile range; LF: lymphatic filariasis; CFA: circulating filarial antigen; STH: soil-transmitted helminths; CI: confidence intervals

^a^ Denominator is equal to total assessed CFA subtracting 22 with smears declined or unreadable (DA N = 1238, IDA N = 2399, Total N = 3637).

^b^ Denominator is equal to total consented for each group.

^c^ Denominator is equal to total consented for each group. Participants received treatment as randomised except 1 in DA received IDA, 123 in IDA received DA.

Parasitic infections {#sec018}
--------------------

Lymphatic filariasis assessments were conducted on 3659 of the eligible 3719 participants aged 2 years and above (98.4%). The reasons for non-testing were: declined blood testing (n = 60); declined a repeat bleed for smear preparation (n = 11); or smear was unreadable due to technical difficulties (n = 11). The prevalence of lymphatic filariasis across the two treatment groups was comparable as measured by detection of CFA (14.1%, 95% CI 11.3--17.5%) and Mf (3.8%, 95% CI 2.6--5.6%, [Table 1](#pntd.0008106.t001){ref-type="table"}, [S6 Table](#pntd.0008106.s009){ref-type="supplementary-material"}). The geometric mean Mf density was also similar between groups (DA 239 Mf/ml, range 17--4643, 95% CI 149--383, versus IDA 183 Mf/ml, range 17--9168, 95% CI 128--260). The intracluster correlation coefficient for Mf was 0.205. Rotuma had a higher CFA prevalence (24.8% versus Gau 6.1%; risk difference (RD) 19.3%, 95% CI 14.1--24.5%) and Mf prevalence (6.9% versus 1.6%; RD 5.6%, 95% CI 2.9--8.2%), but a comparable infection intensity (geometric mean Mf density Rotuma 206 Mf/ml, range 17--9168, 95% CI 148--288, versus Gau 181 Mf/ml, range 17--4492, 95% CI 106--308). Mf prevalence was higher in males (6% versus females 1.6%; RD 4.4%, 95% CI 2.4--6.3%), and those aged 35--49 years had the highest Mf prevalence (7.8%, 95% CI 4.9--12.3%). As the CFA score increased, the proportion with a positive test for Mf also significantly increased; 4.8% of grade 1 CFA were positive for Mf compared to 55.6% of those with CFA scores of 3 (RD 50.6%, 95% CI 41.5--59.6%).

Scabies was evenly distributed across treatment groups with an overall prevalence of 13.5% (95% CI 10.4--17.3%), and prevalence peaking at 32.9% (95% CI 25.7--41.0%) in the children aged 5--9 years. It was more common on Gau (16.9%, 95% CI 12.6--22.2%, versus Rotuma 8.8%, 95% CI 5.6--13.7%, RD 8.5%, 95% CI 2.7--14.4%) and in females (15% versus males 12%, RD 3.0%, 95% CI 1.1--4.9%). The STH prevalence was higher in the IDA groups (20.7%, 95% CI 13.2--30.9%) compared to the DA group (13.1%, 95% CI 6.3--25.1%, RD 5.3%, 95% CI 0--10.5%). Gau had a higher STH prevalence (25.7%, 95% CI 16.9--37.0%, versus Rotuma 5.0%, 95% CI 2.8--8.8%, RD 20.1%, 95% CI 10.8--29.5%), as did males (23.5%, 95% CI 17.1--31.6%, versus females 13.8%, 95% CI 8.2--22.2%, RD 10.9%, 95%CI 5.3--16.4%). Children aged 10--14 years had the highest STH prevalence (30.1%, 95% CI 13.3--54.6%).

One infection (either filariasis, scabies or STH), was identified in 1136 participants (29.8% of enrolled). Sixty-one participants had two infections identified and three participants were co-infected with all three.

Treatment {#sec019}
---------

A majority of participants were eligible and received filariasis treatment according to the assignment of their village (94% and 95.1% in DA and IDA groups respectively). One person in the DA group received IDA and 123 in the IDA group received DA (due to exclusion from ivermectin because of weight and/or age). Thirty-two of the 305 (10.5%) participants with scabies in the IDA group were ineligible for ivermectin and received permethrin instead on day 0. The 164 participants with scabies in the DA group did not receive permethrin treatment until day 8, after safety monitoring period was completed. Applying intention to treat principles, we included these individuals for analysis in their village randomisation groups and not by the individual treatment they received.

Adverse events {#sec020}
--------------

Of the 3612 participants who received MDA, 14 (0.4%) were lost to follow-up during the 7-day safety monitoring period following treatment ([Fig 1](#pntd.0008106.g001){ref-type="fig"}). One participant was not seen during the two-day active monitoring period but presented to the study nurse for review on day 5.

One or more AE was reported by 600 (16.7%) participants ([Table 2](#pntd.0008106.t002){ref-type="table"}, [S6 Table](#pntd.0008106.s009){ref-type="supplementary-material"}), with symptoms first starting during the active monitoring period for 92.7%. AE rates did not differ by treatment group, and similar AE frequencies were reported after the two treatments in males (DA 15.9% versus IDA 15.1%, *P* = 0.80) and in persons with microfilaremia (DA 45.7% versus IDA 41.9%, *P* = 0.34). Participants found to have scabies on examination reported AEs less frequently than those without (14.3% vs 17.0%, *P* = 0.24). This difference was most marked in the DA group (12.2% AEs in participants with scabies versus 17.4% without scabies, *P* = 0.04) compared to the IDA group (15.4% with scabies versus 16.9% without, *P* = 0.67). There were 121 children aged less than 5 years in the IDA group that received DA and permethrin and were followed up. Of these, six (5.0%) experienced an AE. There were 32 that had scabies and two (6.3%) experienced an AE. In contrast, there were 56 children aged less than 5 years in the DA group that received DA and were followed up. Six (10.7%) experienced an AE. None of the 12 participants with scabies in this sub-group reported an AE, noting that they also did not receive scabies directed treatment until day 8. We found a similar difference in AE reporting based on STH results (13.9% AEs with STH positive stool versus 18.4% STH negative, *P* = 0.13). We observed a similar frequency of AEs when we excluded children aged less than 5 years (DA 17.0% versus IDA 17.3%, *P* = 0.90).

10.1371/journal.pntd.0008106.t002

###### Frequency of adverse events by treatment group.

![](pntd.0008106.t002){#pntd.0008106.t002g}

                                                                                                                      DA     IDA          Total                                              
  ------------------------------------------ ------------------------------------------------------------------------ ------ ------------ ------- ---------- ----- ------------ ------ ----- ------
  Any AE                                     Total treated LF and followed up[^b^](#t002fn003){ref-type="table-fn"}   1216   203          16.7    2382       397   16.7         3598   600   16.7
  Island                                     Rotuma                                                                   412    55           13.3    1152       203   17.6         1564   258   16.5
                                             Gau                                                                      804    148          18.4    1230       194   15.8         2034   342   16.8
  Sex                                        Male                                                                     642    102          15.9    1241       188   15.1         1883   290   15.4
                                             Female                                                                   574    101          17.6    1141       209   18.3         1715   310   18.1
  Age (years)                                Reported AE median (IQR)                                                 41     (19.5--55)   33      (15--49)   36    (16--51.5)                
                                             2--4                                                                     56     6            10.7    123        6     4.9          179    12    6.7
                                             5--9                                                                     181    22           12.2    356        36    10.1         537    58    10.8
                                             10--14                                                                   172    13           7.6     358        48    13.4         530    61    11.5
                                             15--24                                                                   132    17           12.9    322        60    18.6         454    77    17.0
                                             25--34                                                                   146    27           18.5    247        53    21.5         393    80    20.4
                                             35--49                                                                   235    50           21.3    442        96    21.7         677    146   21.6
                                             50--64                                                                   206    50           24.3    358        69    19.3         564    119   21.1
                                             ≥65                                                                      88     18           20.5    176        29    16.5         264    47    17.8
  LF[^a^](#t002fn002){ref-type="table-fn"}   CFA negative                                                             1030   155          15.0    2035       307   15.1         3065   462   15.1
                                             Total CFA positive                                                       184    48           26.1    328        89    27.1         512    137   26.8
                                             CFA1---weak positive                                                     63     14           22.2    107        22    20.6         170    36    21.2
                                             CFA2---medium positive                                                   59     15           25.4    97         25    25.8         156    40    25.6
                                             CFA3---strong positive                                                   62     19           30.6    124        42    33.9         186    61    32.8
  LF                                         Microfilariae negative                                                   1167   182          15.6    2249       354   15.7         3416   536   15.7
                                             Microfilariae positive                                                   46     21           45.7    93         39    41.9         139    60    43.2
  Scabies                                    Not identified                                                           1052   183          17.4    2077       350   16.9         3129   533   17.0
                                             Identified                                                               164    20           12.2    305        47    15.4         469    67    14.3
  STH                                        Negative microscopy                                                      226    40           17.7    504        94    18.7         730    134   18.4
                                             Positive microscopy                                                      35     5            14.3    131        18    13.7         166    23    13.9

DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; AE: adverse event; IQR: interquartile range; LF: lymphatic filariasis; CFA: circulating filarial antigen; STH: soil-transmitted helminths.

^a^ Total assessed for LF CFA N = 3577 (2 in DA and 19 in IDA weren't assessed for LF).

^b^ Participants received treatment as randomised except 1 in DA village received IDA, and 121 in IDA villages received DA (ineligible for ivermectin due to weight and/or age).

The type and severity of AEs was similar across treatment groups ([Fig 2](#pntd.0008106.g002){ref-type="fig"}, [S7 Table](#pntd.0008106.s010){ref-type="supplementary-material"}). Fatigue was the most common AE with 307 (51.2%) of participants who experienced an AE reporting this symptom. Of reported events, 93.2% were graded as mild, 5.5% moderate and 1.3% severe. Symptoms reported as severe by 8 participants (0.2% of participants treated and followed up) were fatigue, headache, dizziness, myalgia, diarrhoea, rash, dyspnoea and chills. There was no life-threatening AE in either treatment group. Eighteen (3.2%) had an AE that persisted beyond 48 hrs following treatment and 44 (7.3%) experienced their first AE after 48 hrs. Only two participants had persistent AEs with severity greater than mild by day 7 after treatment.

![Type, frequency and severity of adverse event symptoms by treatment group, reported as a percentage of total number of participants treated and followed up.\
DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; AE: adverse event. ^a^ Denominator total treated and followed up N = 3598.](pntd.0008106.g002){#pntd.0008106.g002}

In the 139 participants with microfilaremia that were treated, arthralgia (n = 8, 17.4%) and fatigue (n = 7, 15.2%) were the most common symptoms experienced in the DA group. Whereas fatigue (n = 23, 24.7%), arthralgia (n = 13, 14.0%), and muscle weakness (n = 12, 12.9%) were the most common in the IDA group. Fever and scrotal pain, two other commonly reported symptoms following filariasis treatment in the presence of microfilaremia, were reported in 2.9% (n = 3, 6.5% in DA and n = 1, 1.1% in IDA group, *P* = 0.11) and 2.2% (equal in both groups) respectively. There was only one participant in each treatment group with a severe AE. In a post-hoc analysis of participants with microfilaremia, the geometric mean Mf density was significantly higher in those that experienced an AE after treatment (357 Mf/ml, 95% CI 223--569 versus 131 Mf/ml, 95% CI 95--181, ttest *P* = 0.0004).

In the 469 participants with scabies that were treated for filariasis, 67 (14.3%) reported an AE, and a higher proportion were in the IDA group (n = 47, 15.4% versus DA n = 20, 12.2%, *P* = 0.61). In this scabies sub-group, fatigue remained the most common symptom (DA n = 10, 6.1% versus IDA n = 23, 7.5%, *P* = 0.71). Abdominal pain was reported more in both treatment groups with scabies (DA n = 2, 1.2% and IDA n = 3, 1.0%) compared to all participants (n = 18, 0.5%, *P* = 0.22). In the IDA group with scabies compared to the whole cohort, there was notable increased reporting of pruritus (n = 7, 2.3% versus n = 36, 1.0%, *P* = 0.046 respectively) and rash (n = 5, 1.6% versus n = 15, 0.4%, *P* = 0.016 respectively). Only one participant who reported pruritus in the IDA group received permethrin.

An STH infection was identified in 166 participants and AEs were reported by 23 (13.9%). Gastrointestinal symptoms (nausea, vomiting, diarrhoea, abdominal pain, and abdominal distension) were reported less by members of this sub-group than overall (STH positive DA 0% versus IDA n = 5, 3.8%, versus overall n = 153, 4.3%).

Serious adverse events {#sec021}
----------------------

There were three serious AE reports. One participant who received DA, had dizziness and hypertension requiring overnight hospitalization, six days after treatment, and another in the DA group had an acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization, two days after treatment. One participant with pre-existing lower limb lymphoedema developed cellulitis of the limb five days after IDA treatment. This participant experienced severe limitation of mobility and personal activities of daily living, but did not require hospitalization. All three had complete resolution of their symptoms.

Risk factors for adverse events {#sec022}
-------------------------------

Univariate and multivariate analyses revealed no difference in reporting of AEs between treatment groups or by island locations ([Table 3](#pntd.0008106.t003){ref-type="table"}). Participants aged 50--64 years of age had the highest risk of an AE (adjusted RD 12.5%, 95% CI 5.4--19.6%). We observed a linear relationship between baseline filarial infection status of participants and AE reporting, with 15.1% of participants having a negative CFA test reporting an AE compared to 33.1% of those with a grade 3 CFA test (RD 19.4%, 95% CI 10.5--28.4%). Further, 43.2% of participants with Mf reported an AE compared to 15.8% of those without Mf (adjusted RD 26.4%, 95% CI 18.5--34.3%). Males reported fewer AEs (15.4%) than females (18.1%, adjusted RD 3.5%, 95% CI 0.9--6.1%), despite having a much higher Mf prevalence (6% versus 1.6%). There was no increased risk of reporting of AEs in participants with scabies or STH (Tables [2](#pntd.0008106.t002){ref-type="table"} and [3](#pntd.0008106.t003){ref-type="table"}).

10.1371/journal.pntd.0008106.t003

###### Risk factor analysis for occurrence of adverse events.

![](pntd.0008106.t003){#pntd.0008106.t003g}

                                                                       Total[^a^](#t003fn002){ref-type="table-fn"}   Univariate analysis[^a^](#t003fn002){ref-type="table-fn"}   Multivariate analysis[^a^](#t003fn002){ref-type="table-fn"}^,^[^b^](#t003fn003){ref-type="table-fn"}                                  
  ------------------------------------------- ------------------------ --------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------ ---------------- ------ ----------------
  Treatment                                   DA                       1213                                          203                                                         16.7                                                                                                   Ref                     Ref    
                                              IDA                      2342                                          393                                                         16.8                                                                                                   0.1    (-5.2 to 5.4)    0.4    (-4.8 to 5.5)
  Island                                      Rotuma                   1525                                          254                                                         16.7                                                                                                   Ref                     Ref    
                                              Gau                      2030                                          342                                                         16.8                                                                                                   0.2    (-4.9 to 5.3)    1.5    (-3.4 to 6.4)
  Gender                                      Male                     1853                                          286                                                         15.4                                                                                                   Ref                     Ref    
                                              Female                   1702                                          310                                                         18.2                                                                                                   2.8    (-0.1 to 5.7)    3.5    (0.9 to 6.1)
  Age (years)                                 2--4                     156                                           11                                                          7.1                                                                                                    Ref                     Ref    
                                              5--9                     537                                           58                                                          10.8                                                                                                   3.7    (-0.5 to 7.8)    3.2    (-1.5 to 7.9)
                                              10--14                   526                                           61                                                          11.6                                                                                                   4.5    (-0.1 to 9.1)    4.5    (-0.3 to 9.3)
                                              15--24                   453                                           77                                                          17.0                                                                                                   9.9    (4.1 to 15.7)    9.7    (3.6 to 15.9)
                                              25--34                   393                                           80                                                          20.4                                                                                                   13.2   (8 to 18.5)      11.9   (6.5 to 17.3)
                                              35--49                   671                                           143                                                         21.3                                                                                                   14.2   (9.7 to 18.7)    11.7   (6.5 to 17)
                                              50--64                   557                                           119                                                         21.4                                                                                                   14.3   (7.9 to 20.7)    12.5   (5.4 to 19.6)
                                              ≥65                      262                                           47                                                          17.9                                                                                                   10.8   (5.1 to 16.6)    9.1    2.7 to 15.4)
  LF                                          Total CFA negative       3065                                          462                                                         15.1                                                                                                   Ref                     \-     \-
                                              Total CFA positive       490                                           134                                                         27.3                                                                                                   13.4   (7.8 to 19.1)    \-     \-
                                              CFA1---weak positive     165                                           35                                                          21.2                                                                                                   7      (-0.4 to 14.3)   \-     \-
                                              CFA2---medium positive   147                                           40                                                          27.2                                                                                                   13.4   (5.1 to 21.8)    \-     \-
                                              CFA3---strong positive   178                                           59                                                          33.1                                                                                                   19.4   (10.5 to 28.4)   \-     \-
  LF                                          Microfilariae positive   139                                           60                                                          43.2                                                                                                   28.2   (20.6 to 35.7)   26.4   (18.5 to 34.3)
  Scabies                                     Identified               461                                           67                                                          14.5                                                                                                   -2.6   (-7 to 1.8)      1.3    (-2.8 to 5.5)
  STH[^c^](#t003fn004){ref-type="table-fn"}   Positive microscopy      165                                           23                                                          13.9                                                                                                   -4.9   (-10.6 to 0.8)   \-     \-

RD: risk difference; CI: confidence interval; Ref: reference group; DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; LF: lymphatic filariasis; CFA: circulating filarial antigen; STH: soil-transmitted helminths.

^a^ Denominator for total, univariate and multivariate analyses' N = 3555 (excluded 21 declined CFA testing, 11 unreadable Mf smears, 11 declined Mf smears).

^b^ Multivariate risk difference analysis excludes CFA scores and STH results.

^c^ Denominator for STH analysis N = 881.

Discussion {#sec023}
==========

Our study demonstrates that community MDA with IDA has a similar AE profile to the traditional DA combination in Fiji. Approximately one in every six individuals treated experienced an AE, but the vast majority of these events were mild and resolved within seven days. Fatigue, headache, dizziness, nausea and arthralgia were the five most common symptoms reported. The type of AEs in our study were consistent with those reported in previous studies.\[[@pntd.0008106.ref008], [@pntd.0008106.ref013], [@pntd.0008106.ref036]\]

The safety of IDA has been demonstrated in small randomised trials\[[@pntd.0008106.ref008], [@pntd.0008106.ref010]\], and now in a large multi-site community safety trial that included Fiji.\[[@pntd.0008106.ref013]\] However, these studies have not reported on the effect of scabies and STH infections on the reporting of AEs. The Fiji results we report here, clearly outline the community prevalence of each neglected tropical disease and their relationship to reporting of AEs following IDA compared to DA. Despite a high burden of scabies and STH there was no increased reporting of AEs in persons with these infections.

As expected, we observed a strong positive relationship between markers of filarial infection and the frequency of AEs.\[[@pntd.0008106.ref011]\] This was most prominent among participants with microfilaremia detected by the 60 μl smear. However, it was also observed in participants who were CFA positive without microfilaremia. Since most AEs are attributed to death of Mf \[[@pntd.0008106.ref011]\], it is possible that these participants had low density microfilaremia that was not detected by smear, or Mf were not circulating at the time of testing. This uncertainty around presence of Mf might have been avoided if we used the more sensitive method of membrane filtration with 1ml venous blood, but this is not practical for large numbers in this study.\[[@pntd.0008106.ref037]\] We observed fever in participants with microfilaremia less frequently than expected from the smaller safety trials.\[[@pntd.0008106.ref008]--[@pntd.0008106.ref010]\] This may have been due to reduced intensity of monitoring in our study and the absence of other febrile infectious syndromes including malaria. We noted that women were more likely to report an AE despite being less likely to have microfilaremia. This gender difference has been reported in other studies \[[@pntd.0008106.ref010], [@pntd.0008106.ref013]\], and is hypothesised to be because women are more likely to report subjective AEs than men.

There are a number of strengths to our study. First, the randomisation of villages achieved balance of treatment groups with regard to baseline demographic characteristics, prevalence of filariasis and scabies, numbers of people treated and monitored for AEs. Second, we maintained high participation over 7 days of safety monitoring, with only 14 participants lost to follow-up. It is unlikely that these participants experienced a severe or serious AE that went undetected due to the close proximity of the study team to the local health care providers.

Our study was limited by the inability to blind participants and assessors to the treatment group. In a safety study of this kind, blinding would have been ideal, but was not feasible, largely because of the addition of a topical treatment to the intervention, as well as the logistics of providing a second dose to all participants. A further limitation of the study is the relatively small number of participants in our sub-analyses, meaning that cautious interpretation is required for risk differences.

Current modelling suggests that MDA coverage above 65% is required for success of the strategy to interrupt transmission.\[[@pntd.0008106.ref038], [@pntd.0008106.ref039]\] After more than 10 rounds of MDA for filariasis in the study sites, the risk of participation fatigue increases and therefore likelihood of high MDA coverage decreases.\[[@pntd.0008106.ref040], [@pntd.0008106.ref041]\] Comprehensive community engagement is recognised as crucial for success of the introduction of the new IDA strategy.\[[@pntd.0008106.ref014]\] In our experience, highlighting the action of the IDA MDA on the three common infections found at our study sites prior to enrolment, assisted in our high population coverage for MDA. This message can now be coupled with the findings of the study that the combination of the three drugs for MDA is safe.

Our study describes the large burden of neglected tropical diseases in Fiji that may benefit from IDA. Our results confirm that introducing MDA using IDA as an elimination strategy for lymphatic filariasis in Fiji is as safe as the current DA combination that has been implemented and accepted by communities since 2002. Our results provide confidence for the safety of IDA within other Pacific populations where lymphatic filariasis remains endemic, along with scabies and soil-transmitted helminths.

Supporting information {#sec024}
======================

###### Community Based Safety of 2-drug (Diethylcarbamazine and Albendazole) versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis in Fiji--Protocol v6.0 6^th^ August 2019.

(PDF)

###### 

Click here for additional data file.

###### Randomisation, treatment and monitoring flowchart.

DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two dose with DA; AE: adverse event.

(PDF)

###### 

Click here for additional data file.

###### Adverse event monitoring flowchart.

AE: adverse event; PI: principal investigator; HREC: human research ethics committee. ^a^ Passive monitoring: participants asked to seek out study monitors if grade 1 symptoms worsen or new symptoms develop. All participants with symptoms higher than grade 1 will be actively followed.

(PDF)

###### 

Click here for additional data file.

###### Medication dosing schedule.

(PDF)

###### 

Click here for additional data file.

###### Adverse event grading chart.

(PDF)

###### 

Click here for additional data file.

###### CONSORT 2010 checklist of information to include when reporting a cluster randomised trial.

(PDF)

###### 

Click here for additional data file.

###### Population and participant demographics by village.

DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two dose with DA; IQR: interquartile range.

(PDF)

###### 

Click here for additional data file.

###### Demographics of non-participants in 2017.

DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two dose with DA; Pop.: population; Med.: median; IQR: interquartile range.

(PDF)

###### 

Click here for additional data file.

###### Baseline parasitic infection prevalence and adverse events by village.

DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two dose with DA; IQR: interquartile range; LF: lymphatic filariasis; CFA +: circulating filarial antigen positive; Mf +: microfilariae positive; STH: soil- transmitted helminths; AE: adverse event. ^a^ Denominator tested for CFA excludes n = 60 declined and n = 93 ineligible. ^b^ Denominator for Mf excludes n = 11 unreadable smears, n = 71 declined and n = 93 ineligible. ^c^ Denominator for AE excludes n = 200 not treated and n = 14 lost to follow-up.

(PDF)

###### 

Click here for additional data file.

###### List of reported adverse event symptoms with associated severity in order of frequency in participants treated for filariasis and followed up.

AE: adverse event; DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; Mod: moderate severity; NEC: not elsewhere classified.

(PDF)

###### 

Click here for additional data file.
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Dear Dr. Hardy:

Thank you very much for submitting your manuscript \"The safety of combined ivermectin, diethylcarbamazine and albendazole in the setting of multiple neglected tropical diseases: a cluster randomised trial in Fiji\" (\#PNTD-D-19-01467) for review by PLOS Neglected Tropical Diseases. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

When you are ready to resubmit, please be prepared to upload the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed (uploaded as a \"Revised Article with Changes Highlighted\" file); the other a clean version (uploaded as the article file).

\(3\) If available, a striking still image (a new image if one is available or an existing one from within your manuscript). If your manuscript is accepted for publication, this image may be featured on our website. Images should ideally be high resolution, eye-catching, single panel images; where one is available, please use \'add file\' at the time of resubmission and select \'striking image\' as the file type.

Please provide a short caption, including credits, uploaded as a separate \"Other\" file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plosntds/s/content-license> (NOTE: we cannot publish copyrighted images).

\(4\) If applicable, we encourage you to add a list of accession numbers/ID numbers for genes and proteins mentioned in the text (these should be listed as a paragraph at the end of the manuscript). You can supply accession numbers for any database, so long as the database is publicly accessible and stable. Examples include LocusLink and SwissProt.

\(5\) To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

We hope to receive your revised manuscript by Jan 26 2020 11:59PM. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

To submit a revision, go to <https://www.editorialmanager.com/pntd/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Sincerely,

Sabine Specht

Associate Editor
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Deputy Editor
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: The objectives are clearly articulated and the population appropriate for these objectives. The objectives of the paper are to evaluate the safety of IDA in Fiji, providing a detailed account of AEs following MDA in Fiji and an analysis of factors associated with their occurrence including filariasis, scabies, and STH infections. However, this subset of data from Fiji as part of the international study fundamentally compromises the power of the analysis to achieve its objectives of establishing if IDA materially alters the safety profile of DA. While there are unique co-infection rates in Fiji, the approach of the authors to answer safety would have been more informative if the analysis was based on coinfections rather than national boundaries and included data from the entire study.

There are several other aspects of the methods employed for the main study and this sub-group analysis that are limiting for the stated objectives:

1\. there are two fundamental issues missing from the rationale:

A. There is no discussion of the pharmacological aspects of adding ivermectin to this regimen to understand impact on metabolic pathways, risk of drug:drug interactions or transporter interactions, and extrinsic factors such as food effects. A statement on the pharmacology of the three agents would be the minimum expected

B. An evaluation of the impact on these drugs on pathogen/host respoonse to treatments to contextualise the safety data or approach taken is also not presented to justify the methods chosen.

These evaluations would inform the safety methods employed, including laboratory assessments if required, and the nature and duration of adverse events to be of particular interest

2\. 2 days of active and 5 days of passive adverse event follow up should have been justified in the paper, particularly passive reporting as a method to fully elucidate safety differences. It appears practicality and cost driven rather than the optimal approach to establishing relative risk. As a result, the adverse event rates appear unexpectedly low for systematically collected data, even over such a short period of time.

3\. the rationale for not using a standardised toxicity grading scale to ensure consistency of grading across multiple sites, and the training provided for safety assessors to ensure standardisation of approach is also not described

4\. It should be stated if the analysis plan was signed off prior to database lock and unaltered post-lock, and that statistical consideration was made for this sub-group analysis.

5\. The rationale for not blinding the study has also not been made and is a significant compromise to this design.

6\. Contraceptive measures for women of child bearing potential should be described.

7\. It is assumed that a standard question was asked to elicit adverse events from participants. This should be stated.

8\. The training provided to study nurses to ensure consistency between reviewers and grading of events should also be described. Did they all attend formalised training at an investigator meeting? Was this applied internationally?

9\. Were concurrent medications recorded?

10\. Was regulatory approval received?

11\. How were the variable requirements for fed and fasting state handled in the protocol?

The statistical testing performed should comply with ICHE9. A statement about compliance with Declaration of Helsinki would also be expected.

Reviewer \#2: Specific Points:

1\) Line 145: this would be a good section to describe the age inclusion/exclusion differences from the parent study.

2\) Lines 363-4: need the numbers of pruritus in \<5 year old group give the comment about increased pruritis in the IDA group if disproportionately in the children \<5 would be worth noting given they may have scabies not optimally treated with topicals and without ivermectin.

Reviewer \#3: The authors should clarify and delineate between the safety and efficacy on the main objective of the study. More insight and clarity is needed in understanding the study methods, the specific procedures involved in both intervention and data collection, how responses are transcribed and translated, how issues of language barriers had been addressed.

Authors have not pointed out specific hypothesis being tested.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: The rationale for the microfilariae levels chosen to report against should be provided. Mf presence or absence is the analysis of interest for adverse events incidence and severity but the number of infected people is small which limits the conclusions that can be drawn from the study.

There are too many subdivisions and subgroups in the demography. Suggest this is simplified and standardised to 0-28 day, 28 day to 2 year, 3 to 11 years, 12 to 17, 18 to 65, \>65 for age and few subdivisions for Mf unless justified by the biology of response. Height and weight should have been collected and should be reported.

In line 318, it appears that 100 people who were not eligible for ivermectin received it. Under what circumstances and what happened to them?

Caution should be expressed from the relative risk analysis in Table 3. There are too few patients and the risk of Type 1 or 2 errors is not accounted for in the authors presentation.

Line 216 described drug/pathogen interactions as important for adverse events but it is more accurate to describe this as pathogen/host interactions as a result of drug efficacy.

Line 357 p value, if post hoc, should be declared as post hoc.

Outcomes of SAEs are not given.

Reviewer \#2: The ITT reporting of the age 2-5 group as having received ivermectin needs to be supplemented with an analysis of the \"as treated\" population given the pre-specification to treat the only \>5 y/o children with ivermectin. This may or may not have an impact on analyzing the pruritus finding in the two regimens.

Table 2: suggest either an Asterix on the IDA column for the age 2-4 year old group or remove the numbers from the column given they did not receive IDA as per protocol exclusion.

Reviewer \#3: The tables provides substantial information on the findings of the study. However the tables could be summarized further to present the most essential information, the demographic information can be captured in the text.

Footnote on key descriptions of the table should be provided. The discussion should elaborate on key issues of safety identified . The reported AEs should be exhaustively discussed to allay doubt etc.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The conclusions are not supported. There is Insufficient data in this sub-analysis and fundamental questions about the main study that undermine the objectives.

Reviewer \#2: The conclusion of the parent study that triple drug combination is comparable in safety to the two drug standard of care is supported by the size of the study and the results presented in the multinational publication cited (Weil et al PLoS 2019.) In Fiji, adverse events were frequent albeit largely mild with only 3 unrelated SAE's. The results reported from Fiji do not demonstrate an effect of scabies or STH co-endemic infections on adverse events and this is important information for the endemic population of Fiji that remains resistant to MDA of the 2 drug regimen.

Reviewer \#3: More information and discussion is required on how the data can be of hep to advance our understanding safety in this study. The limitations of the analysis needs to come out clearly.

What level of confidence can we have in the finding that the results or findings in DA group compared to IDA, is not due to some form bias. How wide the gap is the confidence intervals as to make a strong case for judging the similarity between the two groups.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: The paper is well written.

Reviewer \#2: (No Response)

Reviewer \#3: Minor revision

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: It is too ambitious to turn this national analysis into a declaration of safe or not safe for the new regimen. The study was not double blinded, and yet it could have been, the follow up duration was inadequate and should have driven by the biology of drug/host and pathogen/host factors. Further, non-standard methods of collecting adverse events and grading them were employed.

Reviewer \#2: The authors report on the safety of the standard of care regimen of diethylcarbamazine (DEC) and albendazole (DA regimen) versus the standard of care plus two doses of ivermectin (IDA1 and IDA2 regimen) and baseline status of scabies or soil-transmitted helmint infections (STH) from Fiji that apparently was part of a multi-national trial of the two regimens for treatment of lymphatic filariasis (LF). Fiji is endemic for LF and notably has previously received 10 rounds pf MDA with DA.

Clarification is needed between the design of the multi-national study that included Fiji and this manuscript from Fiji alone, now submitted and under review. The funding source and grant are the same yet the age of inclusion of children is different ( \>5 in Weil et al, \>2 in Hardy et al) and the total numbers differ (3,419 in Weil et al and 3612 in Hardy et al) that can not be reconciled by the 179 children enrolled in Hardy et al between 2-5 years of age.

The reporting of the data could also be more informative with further explanation of the as treated population. While an ITT analysis is appropriate to report safety results to avoid any interpretations based on post-randomisation events, the fact that children \<5 were not treated per protocol design with ivermectin indicates that the as treated population should also be reported given ivermectin assignment is determined a priori by age.

My suggestion is to present the analysis as originally described in the SAP but to add the "as treated data" for the \<5 particularly in the sub-group with scabies since the next older age group had the largest burden of scabies and the numbers could be meaningful. If in the end the original conclusions are un-changed, this would strengthen the conclusions of safety of the three-drug regimen in Fiji.

Reviewer \#3: The study is novel in the identification of the key issue of safety of combined therapy. The authors though needs to clearly exhaust this in the discussion to satisfy reader quest for information Give that cases of AEs have been reported, those cases all and all are critical to the outcome of the study. They must be exhaustively discussed and all issues clarified. What are the AEs caused by and what can we rely on to strengthen our belief in this.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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31 Jan 2020

Dear Dr. Hardy,

We are pleased to inform you that your manuscript \'The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: a cluster randomised trial\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch within two working days with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Sabine Specht

Associate Editor

PLOS Neglected Tropical Diseases

Jennifer Keiser

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: This is a retrospective analysis of a substudy and, as such, is compromised. In terms of design, the authors have done their best to walk the tight rope between justifying their approach and acknowledging its inherent limitations.

Reviewer \#2: (No Response)

Reviewer \#3: The methods of the study are in conformity with the results and the authors made efforts to address concerns from the first review.

\*\*\*\*\*\*\*\*\*\*

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: It would be helpful to have the investigator\'s assessment of causality for the serious adverse events stated. It is often helpful to present safety data not just by incidence, but by severity (i.e toxicity grading scale) and investigator assessment of causality as well. It gives the reviewer a better perspective of the importance of what is seen.

Reviewer \#2: (No Response)

Reviewer \#3: The results sections is in conformity with the CONSORT (Consolidated Reporting Of trials) and much clearer for a general grasp of the findings.

\*\*\*\*\*\*\*\*\*\*

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The new language of the conclusions strikes a very reasonable compromise.

Reviewer \#2: (No Response)

Reviewer \#3: A reasonable conclusion have been made as have been supported by the data. The authors can improve on the discussion by giving examples of similar studies and contrast their finding with this whether in agreement or not. Good Luck

\*\*\*\*\*\*\*\*\*\*

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: None.

Reviewer \#2: (No Response)

Reviewer \#3: Minor Revision

\*\*\*\*\*\*\*\*\*\*

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: the paper provides supportive rather than definitive data on the question of whether or not co-morbidities affect the safety profile. This is useful and helpful information for the field and this should be published. This study was not prospectively designed to address the question being asked and thus was not powered appropriately or blinded. The authors have done a good job of softening the conclusions to be more appropriate to the protocol but a retrospective analysis on a subset with post hoc analyses is not how we should be answering these important questions.

Reviewer \#2: Addressed major comments.

Reviewer \#3: This version of the article is much better written and its objectives are very reflected in both the Methodology and the Results. The methods and results sections are in conformity with the CONSORT (Consolidated Reporting Of trials) statement\'s extension to cluster randomized trials guidelines thereby making the study transparent and reproducible. The approach to analysis is also appropriate.

Best wishes,

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Yaya Camara
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10 Mar 2020

Dear Dr. Hardy,

We are delighted to inform you that your manuscript, \"The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: a cluster randomised trial,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Serap Aksoy

Editor-in-Chief

PLOS Neglected Tropical Diseases

Shaden Kamhawi

Editor-in-Chief

PLOS Neglected Tropical Diseases
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